NATCO gets tentative US FDA approval for Ibrutinib tablets EP News Bureau Apr 10, 2021 NATCO feels that it is eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form…
Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL EP News Bureau Sep 7, 2020 Data from Phase 3 E1912 study showed previously untreated patients aged 70 years or younger treated with ibrutinib plus rituximab…
AbbVie completes acquisition of Allergan EP News Bureau May 13, 2020 The transaction significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in…
J&J bumps up full-year profit view on strength of cancer drugs Reuters Oct 16, 2019 The company is facing more than 13,000 lawsuits tied to anti-psychotic drug Risperdal as well as a range of lawsuits involving its…